Apex Therapeutics Files IND to Initiate Phase 1 Study to Evaluate the Tolerability and Anti-Tumor Effects of APX3330

Indianapolis, IN – June 17, 2016 – ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate the tolerability and anti-tumor effects of the company’s lead drug candidate, APX3330. The initial portion of the phase 1 study will determine the maximum tolerated … Read more…